NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Pancreatic Cancer

Interventions: erlotinib, gemcitabine

Countries: Germany

This observational study will evaluate the impact of rash on survival of patients with metastatic pancreatic cancer treated with erlotinib plus gemcitabine. Further, clinical effectiveness, efficacy and safety will be assessed. Data will be collected for 12 months.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Adults, age \>= 18 years
* Patients with metastatic pancreatic cancer where investigators have decided to give combination therapy of erlotinib and gemcitabine according to Summary of Product Characteristics (SmPC)

Exclusion Criteria:

* Contraindications for erlotinib according to Summary of Products Characteristics (SmPC)

Locations (1)

Cologne, Germany